Abstract library

31 results for "Langer".
#2938 Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report
Introduction: Rectal neuroendocrine tumor (NET), a type of rare tumor, is rather rarer when accompanied by non-Langerhans cells histiocytosis named Erdheim-Chester disease (ECD).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Liu M, Chen L, Guo Y, ...
#2717 64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms
Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Esben Andreas Carlsen
#2725 Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients
Introduction: Surgery is the principal treatment for loco-regional gastroenteropancreatic (GEP) neuroendocrine tumors (NET). However, whether surgery is beneficial in high-grade neuroendocrine neoplasms (NEN) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) is not known.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Hans-Christian Pommergaard
#2787 64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast
Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Mathias Loft
#2871 Increase of Ki-67 Index over Time and Influence on All-Cause Mortality in Patients with Neuroendocrine Neoplasms (NEN)
Introduction: Increase of Ki-67 index in NEN over time in relation to progression and a potential influence on prognosis is scarcely studied.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD Pernille Holmager
#2739 Epigenetic Landscape of Pancreatic Neuro-Endocrine Tumors Reveals Distinct Cells of Origin and Means of Tumor Progression
Introduction: Pancreatic Neuroendocrine Tumors (PanNETs) arise from cells of the Islets of Langerhans. The majority of PanNETs are non-functional and their cell of origin cannot be defined analysing specific hormone production. Cell of origin assessment has proven importance to identify risk factors, prevent tumour development, and tailor treatment in many malignancies. Recent data on super-enhancer signatures has suggested a potential origin of PanNET from α- or β-cells. We and others have shown that distinct epigenetic profiles assessed by DNA methylation (DNAme) characterize genomic and prognostic groups of PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Annunziata Di Domenico
#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1
Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Anand Iyer
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen
#366 Next Generation Sequencing is a Cost Effective and Time Saving Method in Clinical Genetic Screening of Patients with Pheochromocytomas
Introduction: Pheochromocytomas are rare tumours arising from adrenal medulla. Recent findings show that about 30-40% of pheochromocytomas are caused by germline mutations in one of the ten hereto known susceptibility genes: SDHA, SDHB, SDHC, SDHD, SDHAF2, RET, VHL, NF1, TMEM127 and MAD. This list of genes is constantly growing. These ten genes together consist of 128 exons and a genetic screening test is both extensive time-consuming and expensive. We introduce utilizing Next generation sequencing as a fast and cost effective method.
Conference:
Category: Basic
Presenting Author: Mr. Joakim Crona
#630 Pancreatic Polypeptide Cell Hyperplasia Associated with Nonfunctioning Pancreatic Neuroendocrine Tumor: A Case Report
Introduction: A case report of pancreatic polypeptide (PP) cell hyperplasia in association with nonfunctioning pancreatic neuroendocrine tumor (NET).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Aleksandar Prazic